Developing the Vaccines National Strategic Plan

Coordinated by the Office of Infectious Disease and HIV/AIDS Policy (OIDP) in the Office of the Assistant Secretary for Health (OASH), of the Department of Health and Human Services, the Vaccine Plan was developed collaboratively with federal agency partners. Stakeholders and the public had significant input into the development of this plan, through a variety of opportunities for public comment. The Vaccines National Strategic Plan 2021–2025 (Vaccine Plan) is intended to strengthen vaccination infrastructure across both the public and private sectors to prevent vaccine-preventable diseases and to support ongoing monitoring of vaccine safety in the United States. It focuses on policies related to vaccines routinely used across the lifespan to prevent diseases in the United States. Its success depends on the active participation and coordinated action of a broad mix of public and private stakeholders from various sectors.

OIDP will continue to lead coordination of the federal implementation of the Vaccine Plan. Other stakeholders are encouraged to develop implementation plans for vaccines-related issues within their purview. Learn more about the development of the plan.

Vaccines Covered in this Plan

The Vaccine Plan focuses on policies related to routinely used vaccines to prevent diseases in the United States across the lifespan. For example, influenza vaccination for all children and adults age 6 months or older and chickenpox vaccination for all children and adults born in 1980 or later who do not have a health condition for which the vaccine is not recommended. The Vaccine Plan similarly addresses routinely recommended vaccines for specific populations. For example, hepatitis B vaccination for newborns, pertussis vaccination with the tetanus-diphtheria-pertussis vaccine for pregnant people, meningococcal vaccination for people with sickle cell disease, and zoster [shingles] vaccination for adults age 50 years or older.

Additional Resources

 

Content created by Office of Infectious Disease and HIV/AIDS Policy (OIDP)
Content last reviewed